buprenorphine patch Butrans
Selected indexed studies
- Transdermal buprenorphine. (Drugs, 2003) [PMID:12962515]
- Prescription of Controlled Substances: Benefits and Risks. (, 2026) [PMID:30726003]
- Transdermal buprenorphine patch: Potential for role in management of opioid dependence. (Asian J Psychiatr, 2019) [PMID:30772733]
_Worker-drafted node — pending editorial review._
Connections
buprenorphine patch Butrans is a side effect of
Sources
- Transdermal buprenorphine. (2003) pubmed
- Prescription of Controlled Substances: Benefits and Risks. (2026) pubmed
- Transdermal buprenorphine patch: Potential for role in management of opioid dependence. (2019) pubmed
- Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. (2011) pubmed
- Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). (2008) pubmed
- Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain. (2012) pubmed
- Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series. (2022) pubmed
- Buprenorphine Use for Analgesia in Palliative Care. (2024) pubmed
- Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study. (2025) pubmed
- Efficacy of Transdermal Buprenorphine Patch in Postoperative Pain Management in Oral and Maxillofacial Surgery. (2024) pubmed